

Soheila Dolatabadi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2822767/publications.pdf>

Version: 2024-02-01

11
papers

340
citations

1307594

7
h-index

1281871

11
g-index

11
all docs

11
docs citations

11
times ranked

768
citing authors

#	ARTICLE	IF	CITATIONS
1	Cell Cycle and Cell Size Dependent Gene Expression Reveals Distinct Subpopulations at Single-Cell Level. <i>Frontiers in Genetics</i> , 2017, 8, 1.	2.3	149
2	JAK-STAT signalling controls cancer stem cell properties including chemotherapy resistance in myxoid liposarcoma. <i>International Journal of Cancer</i> , 2019, 145, 435-449.	5.1	52
3	FET family fusion oncoproteins target the SWI / SNF chromatin remodeling complex. <i>EMBO Reports</i> , 2019, 20, .	4.5	52
4	Global preamplification simplifies targeted mRNA quantification. <i>Scientific Reports</i> , 2017, 7, 45219.	3.3	20
5	Normal and Functional TP53 in Genetically Stable Myxoid/Round Cell Liposarcoma. <i>PLoS ONE</i> , 2014, 9, e113110.	2.5	19
6	Regulatory mechanisms, expression levels and proliferation effects of the FUS-DDIT3 fusion oncogene in liposarcoma. <i>Journal of Pathology</i> , 2016, 238, 689-699.	4.5	13
7	HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death <i>in vitro</i> and <i>in vivo</i> . <i>Oncotarget</i> , 2016, 7, 433-445.	1.8	12
8	Total mRNA Quantification in Single Cells: Sarcoma Cell Heterogeneity. <i>Cells</i> , 2020, 9, 759.	4.1	7
9	FUS-DDIT3 Fusion Oncoprotein Expression Affects JAK-STAT Signaling in Myxoid Liposarcoma. <i>Frontiers in Oncology</i> , 2022, 12, 816894.	2.8	7
10	Identification of inhibitors regulating cell proliferation and FUS-DDIT3 expression in myxoid liposarcoma using combined DNA, mRNA, and protein analyses. <i>Laboratory Investigation</i> , 2018, 98, 957-967.	3.7	6
11	Different HSP90 Inhibitors Exert Divergent Effect on Myxoid Liposarcoma In Vitro and In Vivo. <i>Biomedicines</i> , 2022, 10, 624.	3.2	3